Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium pyrophosphate + stannous is a **diagnostic radiopharmaceutical kit** marketed as **TechneScan PYP**. It is a sterile lyophilized small-molecule kit containing sodium pyrophosphate and stannous chloride that is reconstituted with technetium Tc 99m sodium pertechnetate to generate a nuclear imaging agent. The radiolabeled pyrophosphate localizes by chemisorption to calcium-containing crystalline deposits, particularly in damaged myocardial tissue and sites of altered osteogenesis, enabling scintigraphic detection. Clinically, it has been used for skeletal imaging, adjunctive diagnosis of acute myocardial infarction, and—when used with Tc 99m for red blood cell labeling—for gated cardiac blood pool imaging and detection of gastrointestinal bleeding. The product has been developed and marketed by Mallinckrodt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium pyrophosphate + stannous.